Published in Eur Urol on January 07, 2015
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer | NCT00678392
Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma (ARCC) | NCT00065468
Axitinib-induced proteinuria and efficacy in patients with metastatic renal cell carcinoma. Int J Clin Oncol (2015) 0.76
Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study. Front Pharmacol (2016) 0.75
Predictive Factors for Second-Line Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Analysis. J Kidney Cancer VHL (2017) 0.75
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma. Oncologist (2016) 0.75
Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy. Int J Clin Oncol (2016) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19
Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol (1999) 8.46
Analysis of survival by tumor response. J Clin Oncol (1983) 5.91
Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? J Clin Oncol (2008) 4.11
The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database. Eur J Cancer (2014) 2.79
Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol (2008) 2.54
Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol (2014) 2.53
Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol (2013) 2.14
Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther (2008) 1.58
Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis. Eur J Cancer (2011) 1.46
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer (2006) 1.12
Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI. J Thorac Oncol (2013) 1.01
Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC). Br J Cancer (2013) 0.96
Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials. Eur J Cancer (2013) 0.95
Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial. Eur Urol (2012) 0.91
Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma. Eur J Cancer (2013) 0.83